Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial
| Autor: | Matthay, Michael A a, d, *, Calfee, Carolyn S a, d, Zhuo, Hanjing d, Thompson, B Taylor e, Wilson, Jennifer G g, Levitt, Joseph E h, Rogers, Angela J h, Gotts, Jeffrey E a, Wiener-Kronish, Jeanine P f, Bajwa, Ednan K e, Donahoe, Michael P i, McVerry, Bryan J i, Ortiz, Luis A j, Exline, Matthew k, Christman, John W k, Abbott, Jason d, Delucchi, Kevin L b, Caballero, Lizette c, McMillan, Melanie c, McKenna, David H l, Liu, Kathleen D a, d |
|---|---|
| Zdroj: | In The Lancet Respiratory Medicine February 2019 7(2):154-162 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|